New Directions in iTTP.

Slides:

Advertisements

Similar presentations

Education program ( system). Education program ( system)

Advertisements

CDK 4 and 6 Inhibitors in HR-Positive Breast Cancer: Implementing Paradigms in Clinical Practice.

Clinical Trials in IBD.

Challenges and Opportunities in the Management of ANCA-Associated Vasculitis.

Overview of GCA. Giant Cell Arteritis: Timely Diagnosis and Emerging Treatment Strategies.

Clinical Considerations in the Management of EGFR-Mutated Advanced NSCLC.

NOACs In Long-term VTE Treatment: A State Of The Art Review

Post-autologous Transplant Therapy for Hodgkin Lymphoma

Improving the Diagnosis and Treatment of Seizures in Long-term Care

Omega-3 Prescriptions vs Supplements in Practice

A Paradigm Shift in PAH.

Optimizing Use of Biological Agents in Ulcerative Colitis

Changing the IBD Paradigm

Renal and Extrarenal Complications of ADPKD: Facilitating Better Patient Care.

Unmet Needs in the Secondary Prevention in ACS

Medication Nonadherence in Gout

Clinical Advances in Type 2 Diabetes and Cardiovascular Risk

New Treatments for CTEPH

Innovative Insulin Combinations: A New strategy for the Person With T2DM.

A Closer Look at Pemphigus Vulgaris: Clinical Challenges and Emerging Treatments.

Panelists. One Size May Not Fit All: A New Aspirin Option for the High-Risk Patient.

Goals. The Truth About Statins: High vs Moderate Dose for Secondary Prevention of CAD.

Improving Risk Assessment and Early Diagnosis in PAH

Overview. Maximizing the Safety of CAR T-Cell Therapy: Prevention, Early Recognition, and Management.

Seizures in the Elderly: Treatment and Special Considerations

The Biology Behind BCL2 as a Target in Myeloma

Evolving Science of PAH Treatment

Gene Therapy: Past, Present, and Future

Patient Selection, Pharmacoeconomics, and PCSK9 Inhibitors

Program Goals Overview Glatiramer Acetate 3 Times a Week.

Improving Therapeutic Management of Huntington's Disease in Long-Term Care.

Advancing the Treatment of IBD With Biologics

Treatment of Thromboembolic Disease The Need for Multiple Perspectives

Treating CD30-Expressing Cutaneous T-Cell Lymphoma

The Evolving Treatment Landscape in Atopic Dermatitis

Program Goals Overview Is NEDA a Reasonable Target?

What Does It Take to Be a Long-Acting Replacement Therapy in Hemophilia A?

Getting to Grips With the Science of CGRP and Migraine

Tackling Schizophrenia With Your Patients

A Time for Change for Managing Patients With VTE Who Have Cancer

Implications of Emerging Treatments for Beta-Thalassemia

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Program Goals Disclaimers Defining Refractory Seizures.

NEDA 2-Year Endpoint: Not a Predictor of Long-Term Stability?

Proteasome Inhibitors and Patients

Goals. The Truth About Statins: High vs Moderate Dose for Secondary Prevention of CAD.

Elevated Admission Plasma Glucose Following ACS

Perspective on the Multidisciplinary Management of PAH

Clinical Challenges and Updates in Managing Seizure Clusters

Assessing the Burden of Hyperkalemia

Practical Strategies for Getting Patients With Diabetes to Lipid Goal

Program Goal. Program Goal Disclaimer Overview.

Program Goals Overview Is NEDA a Reasonable Target?

Peanut Allergy Immunotherapy

Optimizing Outcomes for Patients With Systemic Lupus Erythematosus: Key Considerations.

Strategies for Infection Control in Cystic Fibrosis

Assessing the Burden of Hyperkalemia

Incorporating New PAH Treatments Into Clinical Practice

Would Patients With Hemophilia B Benefit From Switching to Extended Half-Life Factor Products?

PAH Pathways: What Do the Data Tell Us?”

Clinical Comparisons in CTEPH

Patient and Clinician Perspectives on Preventive Therapy for Migraine

Merging the Art and Science of Managing nOH in Clinical Practice

Exploring the Use of Adeno-Associated Virus for Gene Therapy

Treatment Advances for RA

Treatment Initiation and Selection in Newly Diagnosed CLL

Advances in Portopulmonary Hypertension

Presentation transcript:

New Directions in iTTP

Program Overview

Improving the iTTP Prognosis

Pathophysiology of iTTP

TTP May Be Associated With Other Conditions

Pathophysiology of iTTP (cont)

Treatment Strategies for TTP Based on Pathophysiologic Model

Diagnosing iTTP

Predicting ADAMTS13 Deficiency Based on Clinical and Standard Biological Features

Predicting ADAMTS13 Deficiency Based on Clinical and Standard Biological Features (cont)

Unmet Needs with Current Treatment

Managing Suboptimal Response to Therapy

New Therapies for iTTP: HERCULES Study

HERCULES Study: Key Results

HERCULES Study: Secondary Endpoints

HERCULES Study: Safety

Recombinant ADAMTS13 for cTTP

Recombinant ADAMTS13 for cTTP (cont)

Preventing Relapse After Therapy for iTTP

Preventing Relapse After Therapy for iTTP (cont)

Outlook With New Therapies

Changing the Treatment Paradigm

Changing the Treatment Paradigm (cont)

Monitoring Long-Term Complications

Abbreviations